Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Eprodisate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | HBB | P68871 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprodisate SCHEMBL218551 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL4422542 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL2288868 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL12979823 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL218553 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL293813 | 0.92 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL2519328 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL11909837 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| SCHEMBL11067237 | 0.89 | GMNN (0.55) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| SCHEMBL14974551 | 0.85 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9118062-B2 | Anode and method of manufacturing the same, and battery and method of manufacturing the same | SONY CORPORATION (JP) | 2015-08-25 | — | — | US | claimed |
| US-RE45310-E1 | Cathode active material, cathode therewith and nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2014-12-30 | — | — | US | claimed |
| US-20080311472-A1 | ANODE AND METHOD OF MANUFACTURING THE SAME, AND BATTERY AND METHOD OF MANUFACTURING THE SAME | SONY CORPORATION (JP) | 2008-12-18 | — | — | US | claimed |
| US-9118062-B2 | Anode and method of manufacturing the same, and battery and method of manufacturing the same | SONY CORPORATION (JP) | 2015-08-25 | — | — | US | disclosed |
| US-RE45310-E1 | Cathode active material, cathode therewith and nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8613873-B2 | Anode, battery, and methods of manufacturing them | SONY CORPORATION (JP) | 2013-12-24 | — | — | US | disclosed |
| US-8394540-B2 | Anode and method of manufacturing same, secondary battery and method of manufacturing same, and sulfone compound | SONY CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8377589-B2 | Cathode active material, cathode therewith and nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8349489-B2 | Cathode active material, cathode therewith and nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120231335-A1 | CATHODE ACTIVE MATERIAL, CATHODE THEREWITH AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | SONY CORPORATION (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20110250509-A1 | SECONDARY BATTERY AND ELECTRONIC DEVICE | SONY CORPORATION (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20090263726-A1 | ANODE AND METHOD OF MANUFACTURING SAME, SECONDARY BATTERY AND METHOD OF MANUFACTURING SAME, AND SULFONE COMPOUND | SONY CORPORATION (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090202905-A1 | CATHODE ACTIVE MATERIAL, CATHODE THEREWITH AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | SONY CORPORATION (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090169985-A1 | ELECTROLYTIC SOLUTION, SECONDARY BATTERY AND METHOD OF MANUFACTURING SAME, AND SULFONE COMPOUND | SONY CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090136855-A1 | ANODE, BATTERY, AND METHODS OF MANUFACTURING THEM | SONY CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20080311472-A1 | ANODE AND METHOD OF MANUFACTURING THE SAME, AND BATTERY AND METHOD OF MANUFACTURING THE SAME | SONY CORPORATION (JP) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263726-A1 | ANODE AND METHOD OF MANUFACTURING SAME, SECONDARY BATTERY AND METHOD OF MANUFACTURING SAME, AND SULFONE COMPOUND | STS, ASH2L, CACNA2D2 | ALDH1A1 1556/4885SMN1; SMN2 1357/4885GMNN 2873/4885 |
| US-20090169985-A1 | ELECTROLYTIC SOLUTION, SECONDARY BATTERY AND METHOD OF MANUFACTURING SAME, AND SULFONE COMPOUND | CA12, CA1, STS | ALDH1A1 502/4885SMN1; SMN2 855/4885GMNN 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.